FDA Alerts

The US Food and Drug Administration (FDA) has indicated nivolumab for intravenous use in patients with previously treated liver cancer.

The US Food and Drug Administration (FDA) expanded the approval of a targeted therapy to treat gastric or gastroesophageal junction (GEJ) cancer.

The US Food and Drug Administration recently approved the first single dose once-daily inhaler to be used as maintenance therapy for patients with chronic obstructive pulmonary disease.

The US Food and Drug Administration has approved a new option for the treatment of bacterial vaginosis in adult women.

The US Food and Drug Administration has approved a generic oral suspension of a common influenza drug to prevent and treat the virus in adults and children.

The FDA has approved new indication for 2 previously-approved treatment option for partial-onset seizures.

The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.

The US Food and Drug Administration has approved a new treatment option for adult and pediatric patients with CD33-positive acute myeloid leukemia.

After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.

The FDA has approved the first CAR T-cell therapy available in the United States for the treatment of certain pediatric patients.